Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | 13.4% | 14.3% | 6.5% | 13.5% | 14.9% | 13.6% | 12.3% | 12.1% | 15.8% | 5.7% | 5.6% | 7.3% | 7.3% | (0.3%) | 5.0% | 7.2% | 8.3% | 11.9% | 11.5% | 9.4% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 9.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Abbott Laboratories have been 11.0% over the past three years, and 10.4% over the past five years.
As of today, Abbott Laboratories's Return on Capital Employed (ROCE) is 9.9%, which is higher than industry median of (21.9%). It indicates that Abbott Laboratories's Return on Capital Employed (ROCE) is Good.